Key clinical point: A retrospective study suggests bone marrow involvement and actual body weight are predictive of rituximab infusion-related reactions in patients with lymphoid malignancies.
Major finding: Greater bone marrow involvement and actual body weight were significantly associated with rituximab infusion-related reactions (P = .003 and P = .01, respectively).
Study details: A retrospective analysis of 173 patients with a lymphoid malignancy who received initial rituximab therapy as an inpatient, including 81 patients with DLBCL.
Disclosures: No funding sources were reported. The authors reported having no conflicts of interest.
Kowalski KE et al. Clin Lymphoma Myeloma Leuk. 2019 Aug 9. doi: 10.1016/j.clml.2019.08.001.